Akihiro Nishiyama

Affiliation and department：

Research field (1)： Tumor diagnostics and therapeutics

Research keywords (2)： analysis about resistant mechanism of molecular targeted therapy , establishment of patient derived cell

Papers (5)：

Nishiyama Akihiro. in vivo imaging xenograft models for the evaluation on anti-brain tumor efficacy of targeted drugs. Cancer Medicine
Nishiyama Akihiro. AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells. Nature Communications
Nishiyama Akihiro. Distribution and activity of lenvatinib in brain tumor models of human anaplastic thyroid cancer cells in severe combined immune deficient mice. Molecular Cancer Therapeutics
Nishiyama Akihiro. Epithelial-to-mesenchymal transition is a mechanism of ALK inhibitor resistance in lung cancer independent of ALK mutation status. Cancer Reseach
Nishiyama Akihiro. Foretinib overcomes entrectinib resistance associated with the NTRK1 G667C mutation in NTRK1 fusion-positive tumor cells in a brain metastasis model. Clinical Cancer Rearch Kanazawa University Graduate

Education (2)：

2015 - 2019 Kanazawa University Graduate
2000 - 2006 Nara Medical University

Work history (1)：

2015/04 - 現在 Kanazawa University Division of Medical Oncology Cancer Research Institute Assistant Professor

Awards (1)：

2011/05 - 西日本がん研究機構 WJOG賞

Association Membership(s) (6)：

日本がん転移学会 , THE JAPANESE ASSOCIATION FOR MOLECULAR TARGET THERAPY OF CANCER , 臨床腫瘍学会 , THE JAPAN LUNG CANCER SOCIETY , THE JAPANESE RESPIRATORY SOCIETY , THE JAPANESE SOCIETY OF INTERNAL MEDICINE

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page